Oral Lichen PlanusNCT07278999
Photobiomodulation, Photodynamic Therapy, and Clobetasol in the Treatment of Oral Lichen Planus.
A study testing Photobiomodulation using 635 nm diode laser, Photodynamic therapy - laser mucosal treatment and Clobetasol propionate 0.05 percent topical application in people with Oral Lichen Planus and Erosive Lichen Planus, run by Medical University of Silesia at 1 site in Poland.
Trial summary
This study aims to compare three treatment approaches for the erosive form of oral lichen planus, a chronic inflammatory condition that often causes pain, impaired oral function, and frequent relapses. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Oral Lichen Planus, Erosive Lichen Planus, Mucosal Lesions
- What is being tested?
- Photobiomodulation using 635 nm diode laser, Photodynamic therapy - laser mucosal treatment and Clobetasol propionate 0.05 percent topical application
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePoland
- Study dates
- 1 Dec 2025to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be between 20 and 70 years old.
- Have histologically confirmed erosive or ulcerative oral lichen planus based on a biopsy.
- Have no active aerobic bacterial infection or oral fungal infection.
- Have had no treatment for OLP within the past 3 months.
- Provide written informed consent.
Who cannot join
- Systemic diseases or conditions such as uncontrolled diabetes (random glucose ≥200 mg/dl), cardiovascular failure, or a pacemaker.
- Autoimmune/connective tissue diseases such as lupus with positive ANA testing.
- Current or past cancer, graft-versus-host disease, or hematologic disorders (anemia, leukemia, lymphoma, bleeding disorders, hemophilia, von Willebrand disease).
- Enzymatic or metabolic disorders such as G6PD deficiency (favism) or porphyria.
- Viral hepatitis A, B, or C.
- Recent vaccinations (within the past 6 months).
Show all 20Show fewer
- Use of medications known to trigger lichenoid reactions, including:
- Antihypertensives (beta-blockers, diuretics, ACE inhibitors, centrally acting agents).
- Oral antidiabetics (sulfonylureas).
- Metal-containing compounds (lithium, gold, arsenic, mercury).
- NSAIDs (e.g., ibuprofen).
- Antibiotics/chemotherapeutics (tetracyclines, sulfonamides).
- Pregnancy or breastfeeding (including up to 6 months post-lactation).
- Photosensitivity to UV light.
- Smoking more than 5 cigarettes per day.
- Lesions located adjacent to amalgam fillings or metal prosthetic restorations.
- Any degree of dysplasia on histopathology.
- Treatment for OLP within the last 3 months.
- Active oral fungal or bacterial infection at screening.
- Lack of consent to participate.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
Department of Periodontology and Oral Mucosa Diseases
Zabrze, Silesian Voivodeship, 41-800
Rafał Wiench, +48 531 770 099, rwiench@sum.edu.pl
About this study
Official title: Effectiveness of Photobiomodulation, Photodynamic Therapy, and Clobetasol in the Treatment of the Erosive Form of Oral Lichen Planus - a Randomized Clinical Trial.
This study aims to compare three treatment approaches for the erosive form of oral lichen planus, a chronic inflammatory condition that often causes pain, impaired oral function, and frequent relapses. Sixty adults with a confirmed diagnosis will be randomly assigned to photobiomodulation, Photodynamic Therapy, or topical clobetasol, which serves as the current standard of care. The project investigates how effectively each method promotes healing of erosive lesions, reduces pain, improves oral functions such as chewing and swallowing, and prevents recurrence after treatment. Before enrollment, participants will undergo microbiological testing, tissue autofluorescence assessment, and histopathological confirmation. Treatment will follow strict protocols tailored to each therapy type, with PBM applied twice weekly, PDT administered once weekly for six consecutive weeks using toluidine blue as a photosensitizer activated by a 635 nm diode laser, and clobetasol used twice daily for thirty days. Clinical outcomes will be measured using lesion size, standardized scoring systems, and patient-reported scales for pain and swelling. Follow up at one week, one month, and three months will document healing progress and relapse rates. Safety monitoring includes evaluation for infections and adverse reactions. The expected outcome is to determine which therapy provides the most effective, safe, and durable improvement. The study may offer evidence supporting laser based methods as alternatives that avoid the risks associated with long term steroid use.
Read the detailed description
The study investigates three therapeutic approaches for managing the erosive form of oral lichen planus, a chronic inflammatory disorder of the oral mucosa characterized by persistent mucosal damage, pain, and the risk of recurrent symptoms. The erosive phenotype is clinically significant because it often leads to functional limitations, such as difficulty eating, impaired tolerance of removable prostheses, and reduced quality of life. Standard therapy relies primarily on potent topical corticosteroids, yet this approach is frequently limited by incomplete remission, recurrence after withdrawal, and the potential for local adverse effects, including mucosal atrophy and secondary candidiasis. For these reasons, alternative treatment modalities have gained increasing clinical interest, particularly those based on light-based therapies capable of modulating cellular processes or removing pathologic tissue with minimal collateral injury. Photobiomodulation and Photodynamic Therapy represent two distinct applications of light energy. Photobiomodulation delivers low energy laser light that supports biological repair mechanisms, reduces inflammatory mediator activity, and enhances tissue regeneration without inducing thermal damage. PDT combines a photosensitizing agent with a light source of specific wavelength, which activates the photosensitizer to generate reactive oxygen species capable of selectively targeting pathologically altered tissue while limiting damage to surrounding healthy mucosa. This contributes to a reduction in lesion activity and supports mucosal recovery through localized cytotoxic and immunomodulatory mechanisms. Although each method has been investigated in smaller clinical series, direct comparisons among photobiomodulation, PDT, and topical corticosteroids remain limited, especially when applied to the erosive variant of oral lichen planus. The study follows a parallel group design with allocation governed by block randomization to maintain balanced group sizes. Participants undergo diagnostic workup before allocation to ensure accurate confirmation of the disease subtype and to exclude other mucosal disorders with overlapping features. Autofluorescence imaging is used as part of the diagnostic process to support precise selection of biopsy site and to assist in distinguishing inflammation from dysplasia or other pathology. Only patients with disease confined to the oral mucosa and without evidence of systemic illness that could influence healing potential proceed to treatment. Interventions are performed using standardized protocols that reflect current best practices for each modality. Photobiomodulation is delivered with a diode laser operating under controlled parameters designed to stimulate repair pathways. The PDT intervention uses toluidine blue as a photosensitizer applied under an occlusive dressing, followed by irradiation with a 635 nm diode laser to activate the photosensitizer and induce targeted cytotoxic effects within the affected mucosa. The control arm uses a topical corticosteroid formulation routinely employed in dental medicine for erosive lesions, with instructions provided to support maximal mucosal contact time. During the treatment period, clinicians document changes in lesion characteristics using standardized measurement tools that allow objective quantification of mucosal surface area and morphological alterations. Photographic records supplement clinical scoring to ensure consistency across follow up visits. Pain severity and functional disturbances are captured with validated numeric scales, supporting a comprehensive evaluation that includes both clinical and patient centered components. Follow up assessments take place after treatment completion to examine the durability of mucosal healing. Given that erosive oral lichen planus often recurs, these visits are critical to understanding whether any modality provides sustained remission. Monitoring includes microbiological evaluation to detect any changes in colonization patterns, such as the emergence of yeast species that may influence treatment response or cause secondary symptoms. Safety oversight focuses on identifying adverse reactions such as erythema, mucosal irritation, delayed healing, dyschromia, or any unexpected tissue responses. Light based methods are generally regarded as safe when applied within established energy ranges, yet ongoing surveillance helps detect rare events or individual sensitivities. The protocol outlines criteria for early discontinuation when significant symptom exacerbation or other concerning findings emerge. This study is structured to deliver high quality comparative data that can guide clinical decision making when standard therapy is insufficient, poorly tolerated, or contraindicated. By evaluating three therapeutically relevant modalities, the study seeks to determine which approach most effectively promotes epithelial recovery, reduces symptom burden, and supports functional comfort. Its focus on recurrence patterns adds an important dimension, as durable improvement is often challenging to achieve in erosive oral lichen planus. The results may clarify the advantages of low level laser applications, the immunomodulatory and antimicrobial properties of PDT, and the role of corticosteroids as a benchmark comparator. Photobiomodulation may demonstrate benefits related to noninvasiveness and absence of steroid related adverse effects. PDT may emerge as a precise alternative capable of controlling symptoms and accelerating mucosal healing through targeted photochemical action while avoiding systemic adverse effects. The study's methodology and extended observation window aim to support evidence based refinements to clinical protocols and promote therapeutic strategies aligned with patient comfort, safety, and long term disease control. The broader significance of the project lies in its potential to improve management of a chronic condition that has meaningful impact on daily activities and overall well being. By integrating structured clinical measurements, patient reported data, and advanced imaging methods, the study seeks to produce a comprehensive dataset that reflects contemporary standards in oral medicine research. The findings may pave the way for future work exploring predictors of treatment success, optimal photosensitizer concentrations and energy parameters for PDT, and potential combination approaches that incorporate both photobiomodulation and photodynamic tissue management.
- Conditions
- Oral Lichen Planus, Erosive Lichen Planus, Mucosal Lesions
- Being tested
- Photobiomodulation using 635 nm diode laser, Photodynamic therapy - laser mucosal treatment, Clobetasol propionate 0.05 percent topical application
- Keywords
- Oral lichen planus, lichen planus, laser, Photobiomodulation therapy, steroids, PDT
- Medical subject headings
- Lichen Planus, Oral, Lichen Planus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Photobiomodulation using 635 nm diode laserDevice
Also called PBM laser therapy, Low level laser therapy (LLLT)
Photobiomodulation is delivered with a 635 nm diode laser in continuous mode at 100 mW, fluence 4 J/cm², and power density 0.2 W/cm². Each point is irradiated for 15 seconds using a noncontact technique with an 8 mm flat glass fiber tip and a 0.5 cm² spot size. Treatment points are spaced 2-3 mm apart over the lesion surface. Sessions are performed twice weekly until complete epithelial healing or for a maximum of eight sessions. This intervention aims to modulate inflammation and support mucosal repair in erosive oral lichen planus.
Photodynamic therapy - laser mucosal treatmentDevice
Photodynamic Therapy is performed using toluidine blue gel as a photosensitizer, applied to the affected mucosal surface under an occlusive dressing for ten minutes. Following removal of the dressing and excess photosensitizer, irradiation is carried out using a 635 nm diode laser (Smart M®, Lasotronix) operating in continuous-wave mode at an output power of 400 mW and a power density of 0.8 W/cm². A flat glass fiber tip of 8 mm diameter is used in a noncontact mode at a distance of approximately 1 mm from the lesion surface. Irradiation is applied point by point at a fluence of 120 J/cm² per point, with the duration of each point irradiation set at 2 minutes and 32 seconds; the total number of points and overall session duration are determined by lesion extent. Following irradiation, the photosensitizer is left in place for an additional three minutes before removal by oral rinsing with water. Sessions are conducted once weekly for six consecutive treatments. This intervention evaluat
Clobetasol propionate 0.05 percent topical applicationDrug
Also called Topical corticosteroid
Participants apply clobetasol propionate 0.05 percent directly to clean, dry oral mucosa twice daily for thirty days. The medication is used according to standard clinical practice for erosive oral lichen planus. The formulation serves as the active comparator to evaluate how laser-based treatments perform relative to conventional corticosteroid therapy. Participants are instructed to avoid eating, drinking, or rinsing for at least 30 minutes after application to ensure adequate mucosal contact.
| Study group | Role | What they receive |
|---|---|---|
| Photobiomodulation (PBM) | Experimental | Participants in this arm receive photobiomodulation using a 635 nm diode laser delivered in continuous mode. Energy parameters follow a fixed protocol with 4 J/cm² fluence, 100 mW power, and 15 seconds per treatment point using a noncontact technique. Applications are performed twice weekly until complete epithelial healing or a maximum of eight sessions. This arm evaluates the regenerative and anti-inflammatory effects of PBM for erosive oral lichen planus. Receives: Device: Photobiomodulation using 635 nm diode laser |
| Photodynamic Laser Therapy - TBO mediated | Experimental | Participants in this arm undergo Photodynamic Therapy using toluidine blue as a photosensitizer activated by a 635 nm diode laser. The protocol applies the photosensitizer in gel form under an occlusive dressing for ten minutes, followed by point-by-point irradiation at a fluence of 120 J/cm² using a glass fiber tip of 8 mm diameter, targeting pathologically altered mucosal tissue while minimizing damage to surrounding healthy epithelium. Treatment is performed once weekly for six consecutive sessions. This arm evaluates whether PDT-mediated photochemical action supports lesion resolution, symptom reduction, and sustained remission in erosive oral lichen planus. Receives: Device: Photodynamic therapy - laser mucosal treatment |
| Topical Clobetasol 0.05 percent | Experimental | Participants receive standard therapy with topical clobetasol propionate 0.05 percent. The medication is applied to clean, dry oral mucosa twice daily for thirty days following clinical guidelines for erosive oral lichen planus. This arm serves as the comparator for evaluating the effectiveness of laser-based treatments relative to established corticosteroid therapy. Receives: Drug: Clobetasol propionate 0.05 percent topical application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in erosive oral lichen planus lesion severity using the REA score
Lesion severity will be measured using the REA scoring system, which evaluates the reticular (R), atrophic (A), and erosive (E) components of oral lichen planus. Each component is quantified from standardized lesion tracings and clinical measurements taken during oral examinations. Scores are calculated according to the protocol formula: REA = (R × 1) + (A × 1.5) + (E × 2). The change in total REA score from baseline reflects the therapeutic effect of each intervention on healing of erosive lesions.
Measured: Baseline to 1 week after completion of assigned treatment
Efficacy Index (EI) for overall treatment response
The Efficacy Index (EI) quantifies overall clinical improvement using the formula defined in the study protocol:
EI = [(total REA score before treatment - total REA score after treatment) ÷ total REA score before treatment] × 100 percent.
EI will be used to categorize outcomes as complete healing, significant improvement, moderate improvement, mild improvement, or no improvement.
Measured: Baseline to 1 week after completion of assigned treatment
Improvement in pain intensity (NB)
NB represents the percentage improvement in pain based on the Visual Analogue Scale (VAS). It is calculated using the formula:
NB = [(VAS before treatment - VAS after treatment) ÷ VAS before treatment] × 100 percent.
NB will classify improvement as complete, significant, moderate, mild, or absent.
Measured: Baseline to 1 week after completion of assigned treatment
Secondary outcomes (5)
Change in lesion size measured in mm²
Lesion surface area will be measured using transparent millimeter-grid foil applied to the mucosal surface. Boundaries of each lesion will be traced and the total area calculated. Changes from baseline will be compared across treatment groups.
Measured: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in pain intensity using the Visual Analogue Scale (VAS)
Pain will be assessed using a 0-10 VAS scale. Participants will report pain at baseline and at follow-up visits. Improvement will be quantified using the protocol-defined formula for pain reduction (NB).
Measured: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in swelling or oral discomfort (subjective assessment)
Participants will evaluate swelling or discomfort on a 0-10 numeric scale. Improvement will be calculated using the protocol-defined formula (NO) to quantify reduction of symptoms after treatment.
Measured: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in clinical grade using the Thonprasom scale (0-5)
Clinical severity of oral lichen planus will be evaluated using the Thonprasom grading system. Each lesion will be assigned a grade based on extent and morphology. Change in score over time will be used to assess therapeutic response.
Measured: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in mycological status of oral mucosa
Oral swabs will undergo mycological analysis to detect presence of Candida species before and after treatment. Results will identify whether any intervention increases or reduces fungal colonization or secondary infection risk.
Measured: Baseline and 1 week after treatment completion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2025
- Study start1 Dec 2025
- Primary completionOct 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral Lichen PlanusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomly assigned to one of three independent treatment arms, each receiving a single intervention throughout the study period. The groups progress through the study simultaneously without crossover, allowing direct comparison of photobiomodulation, Er:YAG laser therapy, and topical clobetasol under a parallel design.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Silesia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Dariusz Skaba, Study chair, Department of Periodontolody and Oral Mucosa Diseases, Medical University of SilesiaJakub Fiegler-Rudol, Principal investigator, Department of Periodontolody and Oral Mucosa Diseases, Medical University of SilesiaRafał Wiench, Study director, Department of Periodontolody and Oral Mucosa Diseases, Medical University of Silesia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07278999
- Sponsor's protocol ID
- BNW/NWN/0052/KB1/124/25
- Other IDs
- BNW-1-151/N/5/K
- Status last verified
- Dec 2025
- First submitted
- 1 Dec 2025
- Last updated
- 30 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the study involves sensitive clinical information and the protocol does not include provisions for external data distribution. Data access is limited to the research team to protect participant privacy and confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Photobiomodulation, Photodynamic Therapy, and Clobetasol in the Treatment of the Erosive Form of Oral Lichen Planus - a Randomized Clinical Trial.
- ClinicalTrials.gov ID
- NCT07278999
- Acronym / sponsor ID
- BNW/NWN/0052/KB1/124/25
- Conditions
- Oral Lichen Planus, Erosive Lichen Planus, Mucosal Lesions
- Keywords
- Oral lichen planus, lichen planus, laser, Photobiomodulation therapy, steroids, PDT
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Medical University of SilesiaUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 12 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare three treatment approaches for the erosive form of oral lichen planus, a chronic inflammatory condition that often causes pain, impaired oral function, and frequent relapses. Sixty adults with a confirmed diagnosis will be randomly assigned to photobiomodulation, Photodynamic Therapy, or topical clobetasol, which serves as the current standard of care. The project investigates how effectively each method promotes healing of erosive lesions, reduces pain, improves oral functions such as chewing and swallowing, and prevents recurrence after treatment. Before enrollment, participants will undergo microbiological testing, tissue autofluorescence assessment, and histopathological confirmation. Treatment will follow strict protocols tailored to each therapy type, with PBM applied twice weekly, PDT administered once weekly for six consecutive weeks using toluidine blue as a photosensitizer activated by a 635 nm diode laser, and clobetasol used twice daily for thirty days. Clinical outcomes will be measured using lesion size, standardized scoring systems, and patient-reported scales for pain and swelling. Follow up at one week, one month, and three months will document healing progress and relapse rates. Safety monitoring includes evaluation for infections and adverse reactions. The expected outcome is to determine which therapy provides the most effective, safe, and durable improvement. The study may offer evidence supporting laser based methods as alternatives that avoid the risks associated with long term steroid use.
Detailed description
The study investigates three therapeutic approaches for managing the erosive form of oral lichen planus, a chronic inflammatory disorder of the oral mucosa characterized by persistent mucosal damage, pain, and the risk of recurrent symptoms. The erosive phenotype is clinically significant because it often leads to functional limitations, such as difficulty eating, impaired tolerance of removable prostheses, and reduced quality of life. Standard therapy relies primarily on potent topical corticosteroids, yet this approach is frequently limited by incomplete remission, recurrence after withdrawal, and the potential for local adverse effects, including mucosal atrophy and secondary candidiasis. For these reasons, alternative treatment modalities have gained increasing clinical interest, particularly those based on light-based therapies capable of modulating cellular processes or removing pathologic tissue with minimal collateral injury. Photobiomodulation and Photodynamic Therapy represent two distinct applications of light energy. Photobiomodulation delivers low energy laser light that supports biological repair mechanisms, reduces inflammatory mediator activity, and enhances tissue regeneration without inducing thermal damage. PDT combines a photosensitizing agent with a light source of specific wavelength, which activates the photosensitizer to generate reactive oxygen species capable of selectively targeting pathologically altered tissue while limiting damage to surrounding healthy mucosa. This contributes to a reduction in lesion activity and supports mucosal recovery through localized cytotoxic and immunomodulatory mechanisms. Although each method has been investigated in smaller clinical series, direct comparisons among photobiomodulation, PDT, and topical corticosteroids remain limited, especially when applied to the erosive variant of oral lichen planus. The study follows a parallel group design with allocation governed by block randomization to maintain balanced group sizes. Participants undergo diagnostic workup before allocation to ensure accurate confirmation of the disease subtype and to exclude other mucosal disorders with overlapping features. Autofluorescence imaging is used as part of the diagnostic process to support precise selection of biopsy site and to assist in distinguishing inflammation from dysplasia or other pathology. Only patients with disease confined to the oral mucosa and without evidence of systemic illness that could influence healing potential proceed to treatment. Interventions are performed using standardized protocols that reflect current best practices for each modality. Photobiomodulation is delivered with a diode laser operating under controlled parameters designed to stimulate repair pathways. The PDT intervention uses toluidine blue as a photosensitizer applied under an occlusive dressing, followed by irradiation with a 635 nm diode laser to activate the photosensitizer and induce targeted cytotoxic effects within the affected mucosa. The control arm uses a topical corticosteroid formulation routinely employed in dental medicine for erosive lesions, with instructions provided to support maximal mucosal contact time. During the treatment period, clinicians document changes in lesion characteristics using standardized measurement tools that allow objective quantification of mucosal surface area and morphological alterations. Photographic records supplement clinical scoring to ensure consistency across follow up visits. Pain severity and functional disturbances are captured with validated numeric scales, supporting a comprehensive evaluation that includes both clinical and patient centered components. Follow up assessments take place after treatment completion to examine the durability of mucosal healing. Given that erosive oral lichen planus often recurs, these visits are critical to understanding whether any modality provides sustained remission. Monitoring includes microbiological evaluation to detect any changes in colonization patterns, such as the emergence of yeast species that may influence treatment response or cause secondary symptoms. Safety oversight focuses on identifying adverse reactions such as erythema, mucosal irritation, delayed healing, dyschromia, or any unexpected tissue responses. Light based methods are generally regarded as safe when applied within established energy ranges, yet ongoing surveillance helps detect rare events or individual sensitivities. The protocol outlines criteria for early discontinuation when significant symptom exacerbation or other concerning findings emerge. This study is structured to deliver high quality comparative data that can guide clinical decision making when standard therapy is insufficient, poorly tolerated, or contraindicated. By evaluating three therapeutically relevant modalities, the study seeks to determine which approach most effectively promotes epithelial recovery, reduces symptom burden, and supports functional comfort. Its focus on recurrence patterns adds an important dimension, as durable improvement is often challenging to achieve in erosive oral lichen planus. The results may clarify the advantages of low level laser applications, the immunomodulatory and antimicrobial properties of PDT, and the role of corticosteroids as a benchmark comparator. Photobiomodulation may demonstrate benefits related to noninvasiveness and absence of steroid related adverse effects. PDT may emerge as a precise alternative capable of controlling symptoms and accelerating mucosal healing through targeted photochemical action while avoiding systemic adverse effects. The study's methodology and extended observation window aim to support evidence based refinements to clinical protocols and promote therapeutic strategies aligned with patient comfort, safety, and long term disease control. The broader significance of the project lies in its potential to improve management of a chronic condition that has meaningful impact on daily activities and overall well being. By integrating structured clinical measurements, patient reported data, and advanced imaging methods, the study seeks to produce a comprehensive dataset that reflects contemporary standards in oral medicine research. The findings may pave the way for future work exploring predictors of treatment success, optimal photosensitizer concentrations and energy parameters for PDT, and potential combination approaches that incorporate both photobiomodulation and photodynamic tissue management.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Participants are randomly assigned to one of three independent treatment arms, each receiving a single intervention throughout the study period. The groups progress through the study simultaneously without crossover, allowing direct comparison of photobiomodulation, Er:YAG laser therapy, and topical clobetasol under a parallel design.
| Arm | Type | Receives |
|---|---|---|
| Photobiomodulation (PBM) | Experimental | Device: Photobiomodulation using 635 nm diode laserParticipants in this arm receive photobiomodulation using a 635 nm diode laser delivered in continuous mode. Energy parameters follow a fixed protocol with 4 J/cm² fluence, 100 mW power, and 15 seconds per treatment point using a noncontact technique. Applications are performed twice weekly until complete epithelial healing or a maximum of eight sessions. This arm evaluates the regenerative and anti-inflammatory effects of PBM for erosive oral lichen planus. |
| Photodynamic Laser Therapy - TBO mediated | Experimental | Device: Photodynamic therapy - laser mucosal treatmentParticipants in this arm undergo Photodynamic Therapy using toluidine blue as a photosensitizer activated by a 635 nm diode laser. The protocol applies the photosensitizer in gel form under an occlusive dressing for ten minutes, followed by point-by-point irradiation at a fluence of 120 J/cm² using a glass fiber tip of 8 mm diameter, targeting pathologically altered mucosal tissue while minimizing damage to surrounding healthy epithelium. Treatment is performed once weekly for six consecutive sessions. This arm evaluates whether PDT-mediated photochemical action supports lesion resolution, symptom reduction, and sustained remission in erosive oral lichen planus. |
| Topical Clobetasol 0.05 percent | Experimental | Drug: Clobetasol propionate 0.05 percent topical applicationParticipants receive standard therapy with topical clobetasol propionate 0.05 percent. The medication is applied to clean, dry oral mucosa twice daily for thirty days following clinical guidelines for erosive oral lichen planus. This arm serves as the comparator for evaluating the effectiveness of laser-based treatments relative to established corticosteroid therapy. |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Be between 20 and 70 years old.
- Have histologically confirmed erosive or ulcerative oral lichen planus based on a biopsy.
- Have no active aerobic bacterial infection or oral fungal infection.
- Have had no treatment for OLP within the past 3 months.
- Provide written informed consent.
Key exclusion criteria (20 listed)
- Systemic diseases or conditions such as uncontrolled diabetes (random glucose ≥200 mg/dl), cardiovascular failure, or a pacemaker.
- Autoimmune/connective tissue diseases such as lupus with positive ANA testing.
- Current or past cancer, graft-versus-host disease, or hematologic disorders (anemia, leukemia, lymphoma, bleeding disorders, hemophilia, von Willebrand disease).
- Enzymatic or metabolic disorders such as G6PD deficiency (favism) or porphyria.
- Viral hepatitis A, B, or C.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Photobiomodulation using 635 nm diode laserAlso: PBM laser therapy, Low level laser therapy (LLLT)Photobiomodulation is delivered with a 635 nm diode laser in continuous mode at 100 mW, fluence 4 J/cm², and power density 0.2 W/cm². Each point is irradiated for 15 seconds using a noncontact technique with an 8 mm flat glass fiber tip and a 0.5 cm² spot size. Treatment points are spaced 2-3 mm apart over the lesion surface. Sessions are performed twice weekly until complete epithelial healing or for a maximum of eight sessions. This intervention aims to modulate inflammation and support mucosal repair in erosive oral lichen planus. | Device | Photobiomodulation (PBM) |
| Photodynamic therapy - laser mucosal treatmentPhotodynamic Therapy is performed using toluidine blue gel as a photosensitizer, applied to the affected mucosal surface under an occlusive dressing for ten minutes. Following removal of the dressing and excess photosensitizer, irradiation is carried out using a 635 nm diode laser (Smart M®, Lasotronix) operating in continuous-wave mode at an output power of 400 mW and a power density of 0.8 W/cm². A flat glass fiber tip of 8 mm diameter is used in a noncontact mode at a distance of approximately 1 mm from the lesion surface. Irradiation is applied point by point at a fluence of 120 J/cm² per point, with the duration of each point irradiation set at 2 minutes and 32 seconds; the total number of points and overall session duration are determined by lesion extent. Following irradiation, the photosensitizer is left in place for an additional three minutes before removal by oral rinsing with water. Sessions are conducted once weekly for six consecutive treatments. This intervention evaluat | Device | Photodynamic Laser Therapy - TBO mediated |
| Clobetasol propionate 0.05 percent topical applicationAlso: Topical corticosteroidParticipants apply clobetasol propionate 0.05 percent directly to clean, dry oral mucosa twice daily for thirty days. The medication is used according to standard clinical practice for erosive oral lichen planus. The formulation serves as the active comparator to evaluate how laser-based treatments perform relative to conventional corticosteroid therapy. Participants are instructed to avoid eating, drinking, or rinsing for at least 30 minutes after application to ensure adequate mucosal contact. | Drug | Topical Clobetasol 0.05 percent |
Primary outcome
Change in erosive oral lichen planus lesion severity using the REA score
Time frame: Baseline to 1 week after completion of assigned treatment
Lesion severity will be measured using the REA scoring system, which evaluates the reticular (R), atrophic (A), and erosive (E) components of oral lichen planus. Each component is quantified from standardized lesion tracings and clinical measurements taken during oral examinations. Scores are calculated according to the protocol formula: REA = (R × 1) + (A × 1.5) + (E × 2). The change in total REA score from baseline reflects the therapeutic effect of each intervention on healing of erosive lesions.
Efficacy Index (EI) for overall treatment response
Time frame: Baseline to 1 week after completion of assigned treatment
The Efficacy Index (EI) quantifies overall clinical improvement using the formula defined in the study protocol: EI = [(total REA score before treatment - total REA score after treatment) ÷ total REA score before treatment] × 100 percent. EI will be used to categorize outcomes as complete healing, significant improvement, moderate improvement, mild improvement, or no improvement.
Improvement in pain intensity (NB)
Time frame: Baseline to 1 week after completion of assigned treatment
NB represents the percentage improvement in pain based on the Visual Analogue Scale (VAS). It is calculated using the formula: NB = [(VAS before treatment - VAS after treatment) ÷ VAS before treatment] × 100 percent. NB will classify improvement as complete, significant, moderate, mild, or absent.
5 secondary outcomes
Change in lesion size measured in mm²
Time frame: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in pain intensity using the Visual Analogue Scale (VAS)
Time frame: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in swelling or oral discomfort (subjective assessment)
Time frame: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in clinical grade using the Thonprasom scale (0-5)
Time frame: Baseline, 1 week, 1 month, and 3 months after treatment completion
Change in mycological status of oral mucosa
Time frame: Baseline and 1 week after treatment completion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because the study involves sensitive clinical information and the protocol does not include provisions for external data distribution. Data access is limited to the research team to protect participant privacy and confidentiality.
Related trials for Oral Lichen Planus
RecruitingObservational study
Salivary IL-8 and Serum IL-6 as Biomarkers for Oral Potentially Malignant Disorders in Smokers and Never-Smokers
Oral Potentially Malignant Disorders, Oral Lichen Planus
Not yet recruiting
Curcumin-mediated Photodynamic Therapy Versus Photobiomodulation in the Treatment of Oral Erosive Lichen Planus
Oral Lichen Planus
Not yet recruiting
Adherence to Topical and Systemic Medications Among Symptomatic Oral Lichen Planus Patients: A Pilot Randomized Clinical Trial
Degree of Adherence of Symptomatic OLP Patients to Their Medications
Active, not recruitingPhase 4
Low Level Laser Therapy With Injectable Platelet Rich Fibrin in Management of Oral Lichen Planus
Oral Lichen Planus
Active, not recruiting
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
Erythroplakia, Fanconi Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dariusz Skaba study chair
Department of Periodontolody and Oral Mucosa Diseases, Medical University of Silesia
Jakub Fiegler-Rudol principal investigator
Department of Periodontolody and Oral Mucosa Diseases, Medical University of Silesia
Rafał Wiench study director
Department of Periodontolody and Oral Mucosa Diseases, Medical University of Silesia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Photobiomodulation using 635 nm diode laser, Photodynamic therapy - laser mucosal treatment and Clobetasol propionate 0.05 percent topical application in people with Oral Lichen Planus and Erosive Lichen Planus, run by Medical University of Silesia at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jakub Fiegler-Rudol, PhD candidate (0048531770099, jakub.fieglerrudol@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in erosive oral lichen planus lesion severity using the REA score (time frame: Baseline to 1 week after completion of assigned treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.